Stratec SE/€SBS
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Stratec SE
STRATEC SE, headquartered in Birkenfeld, Germany, specializes in designing and manufacturing fully automated analyzer systems, software, and smart consumables for the in-vitro diagnostics and life sciences sectors. Founded in 1979, the company operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on automated analyzer systems for clinical diagnostics and biotechnology clients; the Diatron segment offers systems and consumables for low-throughput hematology and clinical chemistry applications; and the Smart Consumables segment develops polymer-based consumables for diagnostics and medical applications. STRATEC primarily serves as an original equipment manufacturer (OEM), collaborating with diagnostic companies to develop products marketed under their brands. The company's global presence includes facilities in Switzerland, the United States, Romania, Hungary, Austria, and China. Its strategic positioning is reinforced by long-term partnerships with leading in-vitro diagnostics companies and a comprehensive technology portfolio that spans the entire value chain, from design and development to regulatory approval and production. (,)
Ticker
€SBS
Sector
Primary listing
XETRA
Employees
1,416
Headquarters
Website
Stratec SE Metrics
BasicAdvanced
€322M
21.77
€1.20
0.45
€0.60
2.30%
Price and volume
Market cap
€322M
Beta
0.45
52-week high
€29.75
52-week low
€23.05
Average daily volume
3.2K
Dividend rate
€0.60
Financial strength
Current ratio
3.021
Quick ratio
1.121
Long term debt to equity
40.454
Total debt to equity
54.374
Dividend payout ratio (TTM)
50.04%
Interest coverage (TTM)
5.20%
Profitability
EBITDA (TTM)
38.318
Gross margin (TTM)
29.52%
Net profit margin (TTM)
5.53%
Operating margin (TTM)
9.84%
Effective tax rate (TTM)
27.65%
Revenue per employee (TTM)
€190,000
Management effectiveness
Return on assets (TTM)
3.73%
Return on equity (TTM)
6.28%
Valuation
Price to earnings (TTM)
21.765
Price to revenue (TTM)
1.204
Price to book
1.36
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
44.629
Free cash flow yield (TTM)
2.24%
Free cash flow per share (TTM)
0.585
Dividend yield (TTM)
2.30%
Forward dividend yield
2.30%
Growth
Revenue change (TTM)
2.10%
Earnings per share change (TTM)
-13.74%
3-year revenue growth (CAGR)
-0.65%
10-year revenue growth (CAGR)
6.10%
3-year earnings per share growth (CAGR)
-18.81%
10-year earnings per share growth (CAGR)
-3.60%
3-year dividend per share growth (CAGR)
-14.20%
10-year dividend per share growth (CAGR)
-1.53%
Bulls say / Bears say
The Development and Services segment delivered 20.5% constant-currency sales growth in the first half of 2025, demonstrating a strong innovation pipeline and robust customer demand (PharmiWeb).
In the first quarter of 2025, consolidated sales increased 12.0% (constant currency: +10.9%) to €60.4 million and the adjusted EBIT margin widened by 350 basis points to 8.9%, showing strong momentum early in the year (PharmiWeb).
Operating cash flow improved 152.3% to €48.7 million in full year 2024, strengthening the balance sheet and supporting investment in strategic R&D and capacity (PharmiWeb).
Consolidated sales in full year 2024 fell 4.9% at constant currency to €257.6 million, indicating the company is struggling to maintain revenue growth (PharmiWeb).
Currency effects in the first half of 2025 reduced the adjusted EBIT margin to 7.2%, down from 8.8% a year earlier, signaling the company remains exposed to FX volatility (PharmiWeb).
Sales in the Analyzer Systems segment decreased by 2.2% at constant currency to €34.9 million in H1 2025, highlighting ongoing weakness in the core instrumentation business (PharmiWeb).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stratec SE stock?
Stratec SE (SBS) has a market cap of €322M as of September 09, 2025.
What is the P/E ratio for Stratec SE stock?
The price to earnings (P/E) ratio for Stratec SE (SBS) stock is 21.77 as of September 09, 2025.
Does Stratec SE stock pay dividends?
Yes, the Stratec SE (SBS) stock pays dividends to shareholders. As of September 09, 2025, the dividend rate is €0.6 and the yield is 2.3%. Stratec SE has a payout ratio of 50.04% on a trailing twelve-month basis.
When is the next Stratec SE dividend payment date?
The next Stratec SE (SBS) dividend payment date is unconfirmed.
What is the beta indicator for Stratec SE?
Stratec SE (SBS) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.